In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops

Drug Development and Industrial Pharmacy

Volumn 36, Issue 11, 2010, Pages 1259-1270

  Bozdag, S ^a,b,c   Weyenberg, W ^a   Adriaens, E ^c   Dhondt, M M M ^c   Vergote, V ^c   Vervaet, C ^c   De Prijck, K ^c   Nelis, H J ^c   De Spiegeleer, B ^c   Ludwig, A ^a   Remon, J P ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HACETTEPE UNIVERSITY   (Turkey)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

EPR; Gentamicin; Irritation study; Ocular minitablet; Radiostability; Vancomycin

Indexed keywords

CARBOMER; GENTAMICIN; STARCH; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CONTROLLED STUDY; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; ELECTRON SPIN RESONANCE; GAMMA IRRADIATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; RADIATION DOSE; STAPHYLOCOCCUS EPIDERMIDIS; TABLET FORMULATION; TABLET FRIABILITY; ULTRAVIOLET RADIATION;

ADHESIVENESS; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; GASTROPODA; GENTAMICINS; HUMANS; MUCOUS MEMBRANE; POLYVINYLS; STAPHYLOCOCCUS EPIDERMIDIS; STARCH; TABLETS; TOXICITY TESTS; VANCOMYCIN;

EID: 77956929964     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003718030     Document Type: Article

References (43)

1. Garg P, Sharma S, Rao GN. (1999). Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology, 106:1319-1323
2. Goldstein HM, Kowalski PR, Gordon YJ. (1999). Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology, 106:1313-1318
3. Foster CS, Azar D, Dohlman CH. (2005). The cornea: Scientific foundations and clinical practice. Philadelphia, USA: Lippincott Williams & Wilkins.
4. Allan BD, Dart JKG. (1995). Strategies for the management of microbial keratitis. Br J Ophthalmol, 79:777-786
5. Weyenberg W, Vermeire A, Dhondt MMM, Adriens E, Kestelyn P, Remon JP, et al. (2004). Ocular bioerodible minitablets as a strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci, 45:3229-3233
6. Wilhelmus KR. (1996). Bacterial keratitis. In: Jay S, ed. Ocular infection and immunity. Saint Louis (MO): CV Mosby, 985-995
7. Pflugfelder SC, Hernandez E, Fliesler SJ. (1987). Intravitreal vancomycin: Retinal toxicity, clearance, and interaction with gentamicin. Arch Ophthalmol, 105:831-837
8. Posyniak A, Zmudzki J, Niedzielska J. (2001). Sample preparation for residue determination of gentamicin and neomycin by liquid chromatography. J Chromatogr A, 914:59-66.
9. Ruszczak Z, Friess W. (2003). Collagen as a carrier for on-site delivery of bacterial drugs. Adv Drug Deliv Rev, 55:1679-1698
10. Chen HY, Williams JD. (1984). The activity of vancomycin and teicoplanin alone and in combination with gentamicin or ampicillin against Streptococcus faecalis. Eur J Clin Microbiol, 3:436-438
11. Lam K, Bayer AS. (1984). In vitro bactericidal synergy of gentamicin combined with penicillin G, vancomycin, or defotaxime against group G streptococci. Antimicrob Agents Chemother, 26:260-262
12. Lowy FD, Chang DS, Lash PR. (1983). Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillinresistant, coagulase-negative staphylococci. Antimicrob Agents Chemother, 23:932-935
13. Zervos MJ, Dembinski S, Mikesell T. (1986). High-level resistance to gentamicin in Streptococcus faecalis: Risk factors and evidence for exogenous acquisition of infection. J Infect Dis, 153:1075-1083
14. Lee VHL, Robinson JR. (1986). Topical ocular drug delivery: Recent developments and future challenges. J Ocul Pharmacol, 2:67-108.
15. Diamond J. (1997). Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging, 11:352-360
16. Doona M, Walsh J. (1995). Use of chloramphenicol as topical medication: Time to cry halt? Br Med J, 310:1217-1218
17. Flach A. (1994). Systemic toxicity associated with ophthalmic medications. J Fla Med Assoc, 81:256-260
18. Salminen L. (1990). Review. Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol, 6:243-249
19. Baudouin C. (1996). Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol, 7:80-86
20. Topalkara A, Güler C, Arici MK. (2000). Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol, 28:113-117
21. Gurtler F, Kaltsatos V, Boisramé B. (1995). Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res, 12:1791-1795
22. Ludwig A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev, 57:1595-1639
23. Ceulemans J, Vermeire A, Adriaens E, Remon JP, Ludwig A. (2001). Evaluation of a mucoadhesive tablet for ocular use. J Control Release, 77:333-344
24. Weyenberg W, Vermeire A, Remon JP, Ludwig A. (2003). Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces. J Control Release, 89:329-340
25. Weyenberg W, Vermeire A, DHaese E, Vanhaelewyn G, Kestelyn P, Callens F, et al. (2004). Effect of different sterilisation methods on the properties of bioadhesive powders and ocular minitablets, and clinical evaluation. Eur J Pharm Sci, 23:77-87.
26. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. (2006). An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm, 310:15-24.
27. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. (2007). Studies on a novel doughnut-shaped minitablet for intraocular drug delivery. AAPS PharmSciTech, 8:E118.
28. Van Haeringen NJ. (1981). Clinical biochemistry of tears. Surv Ophthalmol, 5:84-96.
29. European Pharmacopoeia, 6th ed. (2008). Strasbourg (France): Council of Europe.
30. Adriaens E, Dhondt MM, Remon JP. (2005). Refinement of the Slug Mucosal Irritation test as an alternative screening test for eye irritation. Toxicol In Vitro, 19:79-89.
31. Adriaens E, Remon JP. (1999). Gastropods as an evaluation tool for screening the irritating potency of absorption enhancers and drugs. Pharm Res, 16:1240-1244
32. Adriaens E, Ameye D, Dhondt M, Foreman P, Remon JP. (2003). Evaluation of the mucosal irritation potency of co-spray dried Amioca®/poly(acrylic acid) and Amioca®/Carbopol® 974P mixtures. J Control Release, 88:393-399
33. Callens C, Adriaens E, Dierckens K, Remon JP. (2001). Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J Control Release, 76:81-91.
34. Adriaens E, Dhondt M, Remon JP. (2004). Applications of the Slug Mucosal Irritation test. InVitox-2004, Poland (poster presentation).
35. Diana J, Visky D, Hoogmartens J, Van Schepdael A, Adams E. (2006). Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry. Rapid Commun Mass Spectrom, 20:685-693 (Pubitemid 43236858)
36. Haghedooren E, Diana J, Noszal B, Hoogmartens J, Adams E. (2007). Classification of reversed-phase columns based on their selectivity towards vancomycin compounds. Talanta, 71:31-37
37. Sebhatu T, Angberg M, Ahlneck C. (1994). Assessment of the degree of disorder in crystalline solids. Int J Pharm, 101:237-247
38. Weyenberg W, Bozdag S, Foreman P, Remon JP, Ludwig A. (2006). Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components. Eur J Pharm Biopharm, 62:202-209
39. Gohel MC, Parikh RK, Padshala MN, Sarvaiya KG, Jena DG. (2007). Formulation and optimization of directly compressible isoniazid modified release matrix tablet. Ind J Pharm Sci, 69:640-645
40. Bozdag S, Weyenberg W, Ludwig A. (2005). Rheological evaluation of dispersions, prepared with different non-and gammairradiated bioadhesive cospray-dried powder mixtures. Pharmazie, 60:593-597
41. Phinney RB, Schwartz S, Lee DA, Mondino BJ. (1988). Collagenshield delivery of gentamicin and vancomycin. Arch Ophthalmol, 106:1599-1604
42. ICH. (2006). Note for guidance on impurities in new drug products (CPMP/ICH/2738/99). ICH Topic Q 3B (R2) Impurities in New Drug Products.
43. Bartolotta A, DOca MC, Campisi M, De Caro V, Giandalia G, Giannola LI, et al. (2005). Effects of gamma-irradiation on thehalose-hydroxyethylcellulose microspheres loaded with vancomycin. Eur J Pharm Biopharm, 59:139-146